Ads
related to: discovery of monoclonal antibodies technology
Search results
Results From The WOW.Com Content Network
Ever since the discovery that monoclonal antibodies could be generated, scientists have targeted the creation of fully human products to reduce the side effects of humanised or chimeric antibodies. Several successful approaches have been proposed: transgenic mice , [ 39 ] phage display [ 17 ] and single B cell cloning.
Hybridoma technology is a method for producing large numbers of identical antibodies, also called monoclonal antibodies. This process starts by injecting a mouse (or other mammal) with an antigen that provokes an immune response.
The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens presented on the surfaces of tumors. [3] Monoclonal antibodies can be acquired in the immune system via passive immunity or active immunity. The advantage of active monoclonal antibody therapy is the fact that the immune system will ...
In addition, Milstein foresaw the potential wealth of ligand-binding reagents that could result from applying recombinant DNA technology to monoclonal antibodies and inspired the development of the field of antibody engineering, which was to lead to safer and more powerful monoclonal antibodies for use as therapeutics.
The principle of monoclonal antibody production, called hybridoma technology, was published in 1975 by Georges Köhler and César Milstein, [30] who were awarded the 1984 Medicine Nobel Prize for their discovery together with Niels Kaj Jerne. [31] Muromonab-CD3 was the first monoclonal antibody to be approved for clinical use in humans, in 1986 ...
David R. Soll (born April 29, 1942) is a professor of Biology at the University of Iowa. He is best known for the motion analysis of living cells, the discovery of Candida albicans phenotypic switching and monoclonal antibody technology.